Please login to the form below
Barhemsys
This page shows the latest Barhemsys news and features for those working in and with pharma, biotech and healthcare.
Acacia finally gets FDA okay for first product Barhemsys
Edison analyst predicts drug could reach $387m at peak. The long tale of Acacia Pharma’s efforts to bring its post-operative nausea and vomiting (PONV) drug Barhemsys to market is ... Edison previously predicted Barhemsys could add another $110m
Latest news
-
Acacia eyes February FDA verdict for refiled nausea drug Barhemsys
FDA. The Cambridge, UK company has refiled the marketing application for Barhemsys (intravenous amisulpride) and says the US regulator will give it a rapid review with a proposed action date of ... Acacia was hit hard after the FDA issued complete
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Account Management
-
Competitive Salary Offered
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- GSK discontinues two feladilimab trials in head and neck cancer
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- FDA approves new self-injection administration for Xolair
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
- Merck & Co halts development of potential COVID-19 drug MK-7110
- Virtually, the same: Is it time to rethink congress strategy?
PMHub
Page & Page and Partners
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
